دورية أكاديمية
AURKA gene polymorphisms and central nervous system tumor susceptibility in Chinese children.
| العنوان: | AURKA gene polymorphisms and central nervous system tumor susceptibility in Chinese children. |
|---|---|
| المؤلفون: | Chen YP; Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, 510623, Guangdong, China., Yuan L; Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, Guangdong, China., Lin HR; Faculty of Medicine, Macau University of Science and Technology, Macau, 999078, China., Huang XK; Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, Zhejiang, China., Ruan JC; Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou, 325027, Zhejiang, China. ruanjichen@163.com., Zhuo ZJ; Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, 510623, Guangdong, China. zhenjianzhuo@163.com.; Laboratory Animal Center, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, Guangdong, China. zhenjianzhuo@163.com. |
| المصدر: | Discover. Oncology [Discov Oncol] 2021 Dec 15; Vol. 12 (1), pp. 62. Date of Electronic Publication: 2021 Dec 15. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 101775142 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-6011 (Electronic) Linking ISSN: 27306011 NLM ISO Abbreviation: Discov Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [New York] : Springer, [2021]- |
| مستخلص: | Introduction: Central nervous system (CNS) tumors comprise 15-20% of all malignancies occurring in childhood and adolescence. Previous researches have shown that overexpression and amplification of the AURKA gene could induce multiple human malignancies, with which the connection of CNS tumor susceptibility has not been extensively studied. Material and Methods: In this study, we assessed whether and to what extent AURKA gene single nucleotide polymorphisms (SNPs) (rs1047972 C > T, rs2273535 T > A, rs8173 G > C) were associated with CNS tumor susceptibility, based on a case-control analysis in 191 CNS tumor patients and 248 controls. We determined this correlation using odds ratios (ORs) and 95% confidence intervals (CIs). Results: AURKA gene rs8173 G > C exhibited a crucial function to CNS tumor susceptibility fall-off (GC/CC vs. GG: adjusted OR = 0.68, 95% CI = 0.46-0.998, P = 0.049). In addition, the combined effect of lowering the risk of developing CNS tumors was more pronounced in carriers with 3 protective genotypes than others (adjusted OR = 0.55, 95% CI = 0.31-0.98, P = 0.044). Further stratification analysis illustrated that the existence of rs8173 GC/CC and three protective genotypes lowered CNS tumor risk in some subgroups. Conclusions: Our research suggested that the AURKA gene rs8173 G > C could significantly reduce CNS tumor susceptibility in Chinese children. More functional experiments are needed to explore the role of the AURKA gene rs8173 G > C. (© 2021. The Author(s).) |
| References: | Chromosoma. 2003 Dec;112(4):159-63. (PMID: 14634755) EBioMedicine. 2018 Apr;30:113-119. (PMID: 29544698) Cancer Commun (Lond). 2020 Nov;40(11):641-646. (PMID: 32780923) Lancet. 2018 Aug 4;392(10145):432-446. (PMID: 30060998) Front Physiol. 2018 Aug 17;9:1124. (PMID: 30174615) Mol Carcinog. 2015 Dec;54(12):1668-77. (PMID: 25328151) Clin Oral Investig. 2015 Nov;19(8):1825-32. (PMID: 25697104) Environ Mol Mutagen. 2017 Dec;58(9):701-711. (PMID: 28843004) Biosci Rep. 2018 May 22;38(3):. (PMID: 29678897) J Pathol Transl Med. 2017 Jan;51(1):32-39. (PMID: 28013532) Neurol Clin. 2018 Aug;36(3):533-556. (PMID: 30072070) Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105. (PMID: 34608945) BMC Syst Biol. 2018 Dec 14;12(Suppl 7):118. (PMID: 30547784) Int J Environ Res Public Health. 2020 Oct 08;17(19):. (PMID: 33050100) Semin Cancer Biol. 2018 Aug;51:50-58. (PMID: 29170066) PLoS One. 2017 May 4;12(5):e0175136. (PMID: 28472042) Rev Neurol (Paris). 2019 Dec;175(10):664-678. (PMID: 31526552) Nat Rev Dis Primers. 2015 Jul 16;1:15017. (PMID: 27188790) J Exp Clin Cancer Res. 2018 Oct 11;37(1):247. (PMID: 30305138) J Cancer. 2019 Feb 23;10(6):1370-1374. (PMID: 31031846) Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1727-1757. (PMID: 29200119) Neoplasia. 2007 Sep;9(9):707-15. (PMID: 17898866) J Cancer Res Ther. 2014 Nov;10 Suppl:C102-7. (PMID: 25450266) Prog Neurol Surg. 2018;30:1-11. (PMID: 29241168) Int J Med Sci. 2018 Jan 1;15(2):170-175. (PMID: 29333101) Int J Oncol. 2017 May;50(5):1868-1878. (PMID: 28393219) Handb Clin Neurol. 2016;134:71-95. (PMID: 26948349) Clin Genet. 2000 Oct;58(4):250-64. (PMID: 11076050) Breast Cancer Res Treat. 2011 Dec;130(3):905-16. (PMID: 21630024) Biochem Biophys Res Commun. 2017 Apr 22;486(1):43-48. (PMID: 28242198) JAMA. 2013 Nov 6;310(17):1842-50. (PMID: 24193082) PLoS One. 2017 Feb 2;12(2):e0171583. (PMID: 28152093) Neuro Oncol. 2014 Jul;16(7):896-913. (PMID: 24842956) Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. (PMID: 31675094) Int J Oncol. 2019 Oct;55(4):938-948. (PMID: 31485600) Expert Rev Mol Diagn. 2012 May;12(4):383-94. (PMID: 22616703) Crit Rev Oncol Hematol. 2017 May;113:213-234. (PMID: 28427510) Curr Opin Cell Biol. 2003 Dec;15(6):672-83. (PMID: 14644191) J Oncol. 2019 Sep 15;2019:9074908. (PMID: 31636670) Clin Cancer Res. 2004 Nov 1;10(21):7304-10. (PMID: 15534106) IUBMB Life. 2016 Aug;68(8):634-44. (PMID: 27270838) Pharmgenomics Pers Med. 2021 Jan 19;14:109-115. (PMID: 33500652) EBioMedicine. 2017 Nov;25:50-57. (PMID: 29122619) Mol Cancer. 2015 May 20;14:106. (PMID: 25987188) Med Res Rev. 2016 Nov;36(6):1036-1079. (PMID: 27406026) Int J Biochem Cell Biol. 2018 May;98:89-92. (PMID: 29544896) J Natl Compr Canc Netw. 2020 Nov 02;18(11):1537-1570. (PMID: 33152694) J Gene Med. 2017 Nov;19(11):345-352. (PMID: 28985021) Front Oncol. 2020 Jun 30;10:1040. (PMID: 32733797) Invest New Drugs. 2017 Aug;35(4):524-528. (PMID: 28155045) BMC Cancer. 2019 Sep 14;19(1):919. (PMID: 31521144) PLoS One. 2014 Mar 05;9(3):e90328. (PMID: 24598702) Nat Rev Mol Cell Biol. 2001 Jan;2(1):21-32. (PMID: 11413462) |
| معلومات مُعتمدة: | 81802346 National Natural Science Foundation of China; 2020T130132 China Postdoctoral Science Foundation |
| فهرسة مساهمة: | Keywords: AURKA; CNS tumor; Chinese; Polymorphism; Risk |
| تواريخ الأحداث: | Date Created: 20220224 Latest Revision: 20220226 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8777528 |
| DOI: | 10.1007/s12672-021-00459-w |
| PMID: | 35201446 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2730-6011 |
|---|---|
| DOI: | 10.1007/s12672-021-00459-w |